RVL Pharmaceuticals prices $5M registered direct offering

RVL Pharmaceuticals “announced that it has entered into definitive agreements for the purchase and sale of 11,870,846 of its ordinary shares at a purchase price of $0.4212 per ordinary share in a registered direct offering priced at-the-market under Nasdaq rules. The Company also agreed to issue to the investors unregistered series A-1 warrants to purchase up to 11,870,846 ordinary shares and unregistered series A-2 warrants to purchase up to 11,870,846 ordinary shares. The series A-1 warrants have an exercise price of $0.4212 per share, will be exercisable beginning on the effective date of shareholder approval of the issuance of the shares upon exercise of the series A-1 warrants, and will expire five years following the date of shareholder approval.”